Drug and target discovery
We deliver innovative drug and target discovery science to address to priority health and medical problems.
We have a long-standing and internationally recognised reputation for high-quality, translational research with an overall aim of improved health outcomes.
We deliver innovative drug and target discovery science to address to priority health and medical problems.
Our aim is to understand and apply underlying scientific principles in the rational design of medicines.
This theme comprises two groups: Health services research and Musculoskeletal medicine.
Learn more about how our research helps to shape a better future.
Despite big changes to their medication regimens, people being treated for drug addiction appear to be coping well in the pandemic.
A new prognostic tool developed by an international team led by CTI-Bath paves the way for personalised medicine for cancer patients.
People low on selenium are at risk of paracetamol overdose, even when they follow dosage recommendations, according to research involving Bath.
High-quality lab procedures are even more crucial to identifying effective drugs than previously thought, new research from the University of Bath reveals.
The NHS is changing the way it writes its guidelines for giving injections in hospitals, following groundbreaking research from the University of Bath.
A Bath team has been shortlisted for this year’s Emerging Technologies Competition run by the Royal Society of Chemistry.
Find out more about the companies which where founded by our academics. Some of them have now been acquired by major pharmaceutical companies.
Iksuda Therapeutics creates next-generation ADCs targeting difficult-to-treat cancers, including those that are resistant or refractory to current therapies.
The world’s leading provider of orally inhaled and nasal drug product design and development services - now acquired by Aptar Group.
We are focused on developing novel oral medicines to treat autoimmune/inflammatory, gastrointestinal (GI) and metabolic diseases.
Inhalation is our focus. With more than 20 years’ experience, we can help you succeed in bringing inhaled medicines to market.
Bath ASU produces thousands of life-changing medicines for patients in hospitals across the country.
The Bath-Imperial spin-out Sterix specialised in new-generation steroid-based therapeutics and was acquired by the French pharmaceutical company Ipsen.
Our research centres build a lively research community across intra- and interdisciplinary fields.
We transform innovation, arisen from basic research, to diagnostics and prognostics, medicines design and delivery, leading to personalised medicine.
Our mission is to improve cancer patient outcomes by fostering links between Bath’s scientists and clinicians.
An interdisciplinary group from psychology, biology and biochemistry, pharmacy and pharmacology, physics and computer science and local hospital research teams.
We also support research in faculty- and university-wide interdisciplinary research centres.
We develop technologies to improve biomedical diagnosis, environmental monitoring, industrial bio-processes and our understanding of biological functions.
We translate living systems into mathematical models in order to make quantitative predictions and inform biological experiments.
We are an interdisciplinary research centre bridging science and engineering.
A multidisciplinary centre that brings together researchers with a strong interest in sustainability.
The Institute for Mathematical Innovation delivers multi-disciplinary and mathematically grounded research for real-world, societal and industrial challenges.
Exploring pain. Finding new ways forward.
Explore our state-of-the-art facilities available for teaching, research and industry with expert support from University staff.
A multi-user facility providing protein expression and purification services to researchers across the University and beyond.
We combine cutting-edge analytical equipment with extensive in-house expertise to provide a comprehensive material and chemical characterisation service.
We offer projects over a broad spectrum of subject areas. Projects are available as part of Doctoral Training Partnerships as well as on an individual basis.
Bath hosted multidisciplinary CDT, exploring the boundaries between chemical sciences and engineering.
We train the future generation of interdisciplinary mathematicians, working at the interface of statistics with applied and computational mathematics.
The GW4 BioMed MRC Doctoral Training Partnership aims to develop both medical and non-medical students into the next generation of medical researchers.
We support and enrich the experience of our doctoral researchers and play a key role in developing policy and strategy relevant to doctoral study.
Find out about our PhD degrees, funding opportunities and how to apply.
Apply now for one of our academic positions.
Find out more about research consortia in which we participate.
Find out more about some of our major research grants.
Molecules to Manufacture: Processing and Formulation Engineering of Inhalable Nanoaggregates and Microparticles
Psoriatic arthritis (PsA), an inflammatory arthritis, affects approximately 1 in 3 people with pre-existing psoriasis and up to 400,000 people in England.
Engineering Personalised Cutaneous Hypobaric Microchambers that Deliver Antifungal Gas into the Human Nail to Treat Onychomycosis
The G protein coupled receptor (GPCR) family are proteins that play important roles in virtually every body process, targeted in about a third of all medicines.
Assessing the skin pharmacokinetics of topical drugs, and the bio(in)equivalence of topical drug products, using non-invasive techniques
To develop, validate and implement novel methods for the characterisation of drugs. New products will be produced that have extended shelf lives.
Our internationally recognised centre of excellence covers all the skills you'll need to develop and prescribe medicinal products.